SEC Comment Letter 0000000000-23-012496 to IGM Biosciences, Inc. (IGMS) (CIK 0001496323)
IGM Biosciences, Inc. (IGMS) (CIK 0001496323)
Date: Nov. 14, 2023 · CIK: 0001496323 · Accession: 0000000000-23-012496
AI Filing Summary & Sentiment
File numbers found in text: 333-275519
Letter
United States securities and exchange commission logo November 14, 2023 Fred M. Schwarzer Chief Executive Officer and President IGM Biosciences, Inc. 325 E. Middlefield Road Mountain View, CA 94043 Re:IGM Biosciences, Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275519 Dear Fred M. Schwarzer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James Babikian
Show Raw Text
United States securities and exchange commission logo
November 14, 2023
Fred M. Schwarzer
Chief Executive Officer and President
IGM Biosciences, Inc.
325 E. Middlefield Road
Mountain View, CA 94043
Re:IGM Biosciences, Inc.
Registration Statement on Form S-3
Filed November 13, 2023
File No. 333-275519
Dear Fred M. Schwarzer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: James Babikian